The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...
Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest. | Insilico Medicine has signed ...
Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...
Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...
Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...
When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...
AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...
The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...
With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...
The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results